Company news

Propanc Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer

November 2, 2026

Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients

October 30, 2026

Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients

October 28, 2026

Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability

October 26, 2026

CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

October 22, 2026

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

October 22, 2026

Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells

October 16, 2026

Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer

October 14, 2026

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

October 7, 2026

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

September 29, 2026

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

September 22, 2026

Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

September 16, 2026

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

September 9, 2026

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

August 27, 2026

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

August 18, 2026

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

August 12, 2026

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

August 5, 2026

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

July 21, 2026

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

July 7, 2026

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

July 1, 2026

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

June 16, 2026

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

June 11, 2026

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

June 2, 2026

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

May 19, 2026

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

May 15, 2026

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

May 13, 2026

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

March 23, 2026

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

March 11, 2026

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

March 9, 2026

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

March 2, 2026

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

February 18, 2026

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

February 5, 2026

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

January 27, 2026

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

January 20, 2026

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

January 15, 2026

Propanc Biopharma Provides Shareholder Update

January 13, 2026

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

December 22, 2025

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

December 4, 2025

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

December 1, 2025

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

November 17, 2025

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

November 9, 2025

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

November 3, 2025

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

October 14, 2025

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

October 14, 2025

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

October 6, 2025

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

September 17, 2025

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

September 1, 2025

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

August 19, 2025

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

August 14, 2025

Older news releases →

Decks